Anixa Biosciences' CAR-T Therapy To Start Human Trial For Ovarian Cancer

The FDA has signed off Anixa Biosciences Inc's ANIX application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, developed in partnership with Moffitt Cancer Center.
Anixa Biosciences has an exclusive worldwide license to the technology. The therapeutic product includes engineered T-cells that target the follicle-stimulating hormone receptor (FSHR).
FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries.
Related content: Benzinga's Full FDA Calendar
Price Action: ANIX stock is up 4.76% at $5.50 during the market session on the last check Monday.